Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Overview of attention for article published in Frontiers in Cardiovascular Medicine, January 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 47 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 38,157 followers.

RT @agingdoc1: Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLR…

31 Jan 2022

Reply Repost Favourite

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy https://t.co/s981EalEue

31 Jan 2022

Reply Repost Favourite

RT @AutophagyPapers: Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiti…

27 Jan 2022

Reply Repost Favourite

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy https://t.co/WLsDUvpA3r https://t.co/0TNP1aRu8n

27 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.